Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred Because of Clinical Hyperandrogenism

    January 2006 in “ The Journal of Clinical Endocrinology and Metabolism ”
    Enrico Carmina, F. Rosato, A Janni, Manfredi Rizzo, Rosa Alba Longo
    Image of study
    TLDR Most women referred for excess male hormone symptoms had polycystic ovary syndrome (PCOS), with other conditions being less common.
    In a 2006 study involving 950 women referred for clinical hyperandrogenism, polycystic ovary syndrome (PCOS) was identified as the most prevalent disorder, accounting for 72.1% of cases, with classic anovulatory PCOS at 56.6% and ovulatory PCOS at 15.5%. Other conditions included idiopathic hyperandrogenism (15.8%), idiopathic hirsutism (7.6%), nonclassic adrenal hyperplasia (NCAH) (4.3%), and androgen-secreting tumors (0.2%). The study highlighted that patients with classic PCOS tended to have increased body weight, while those with NCAH were younger, exhibited more hirsutism, and had higher levels of testosterone and other androgens. The findings underscored the dominance of PCOS in hyperandrogenism referrals and the significance of recognizing milder forms of androgen excess.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 1000+ results

      community Quit vaping/smoking = 80% less loss

      in Research/Science  235 upvotes 8 months ago
      Quitting vaping significantly reduced hair loss for a user who was a heavy vaper and also taking finasteride. Some participants suggest nicotine's vasoconstrictive properties may worsen hair loss, while others share personal anecdotes of hair improvement after quitting smoking or vaping.

      community Binding affinity of pyrilutamide!

      in Update  167 upvotes 2 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community TRT. Pyrilutamide. Ru58841. Help

      in Treatment  3 upvotes 8 months ago
      A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

    Related Research

    2 / 2 results